Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says
Biomap, a biotechnology start-up co-established by Baidu founder Robin Li Yanhong and backed by the Hong Kong government, says it has surpassed Alphabet subsidiary AlphaFold in commercialising artificial intelligence foundation models for drug discovery.
Multinational pharmaceutical companies were seeing a “reverse” in the technological gap between Biomap and AlphaFold, Wei Liu, co-founder and CEO of Biomap and former CEO of Baidu Ventures, said in an interview with the South China Morning Post.
“There’s no absolute winner in AI benchmark tests, but in terms of commercialisation and projects developed based on our models, I think we are ahead of AlphaFold,” said Wei. However, AlphaFold had “greater academic influence”, he added.
Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with 88 TCF vendor(s) and 21 ad partner(s), or used specifically by this site or app.
